[go: up one dir, main page]

Himmelfarb et al., 1997 - Google Patents

Dipyridamole inhibits PDGF-and bFGF-induced vascular smooth muscle cell proliferation

Himmelfarb et al., 1997

View PDF
Document ID
6900727525791185495
Author
Himmelfarb J
Couper L
Publication year
Publication venue
Kidney international

External Links

Snippet

Dipyridamole inhibits PDGF-and bFGF-induced vascular smooth muscle cell proliferation. Dipyridamole is the only pharmacologic agent demonstrated to reduce polytetrafluoroethylene (PTFE) graft occlusion in hemodialysis patients. However, the …
Continue reading at www.sciencedirect.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Himmelfarb et al. Dipyridamole inhibits PDGF-and bFGF-induced vascular smooth muscle cell proliferation
US5599844A (en) Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
HAUPT et al. Effect of ibuprofen in patients with severe sepsis: a randomized, double-blind, multicenter study
Price et al. Warfarin-induced artery calcification is accelerated by growth and vitamin D
BESSEY et al. Combined hormonal infusion simulates the metabolic response to injury
Raper et al. Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia
Hall et al. Obesity-induced hypertension. Renal function and systemic hemodynamics.
Dibb et al. the management of long‐term parenteral nutrition
EP0833624B1 (en) Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5770609A (en) Prevention and treatment of cardiovascular pathologies
US5595722A (en) Method for identifying an agent which increases TGF-beta levels
Quan et al. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level
Bessey et al. Early hormonal changes affect the catabolic response to trauma
US6251920B1 (en) Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) Method to determine TGF-β
Wollin et al. Nutrients regulate diamine oxidase release from intestinal mucosa
Halverson et al. Calcium crystal–induced inflammation
Berthoux et al. New subgroup of primary IgA nephritis with thin glomerular basement membrane (GBM): syndrome or association
Lebel et al. Adenocarcinoma of the kidney and hypertension: report of 2 cases with special emphasis on renin
IL94549A (en) Pharmaceutical composition containing glutamine
US6476002B1 (en) Treatment of chronic inflammatory diseases with CM101/GBS toxin
Leyva et al. Physiological hyperinsulinemia is not associated with alterations in venous plasma levels of endothelin-1 in healthy individuals
Visschers et al. Development of hypertriglyceridemia in patients with enterocutaneous fistulas
Gruppo et al. Strokes, cutis marmorata telangiectatica congenita, and factor V Leiden
Chan et al. Acute renal vein thrombosis, oral contraceptive use, and hyperhomocysteinemia